Knorr, Ulla
Simonsen, Anja Hviid
Zetterberg, Henrik
Blennow, Kaj
Willkan, Mira
Forman, Julie
Miskowiak, Kamilla
Hasselbalch, Steen Gregers
Kessing, Lars Vedel
Funding for this research was provided by:
Copenhagen University
Article History
Received: 27 March 2023
Accepted: 22 December 2023
First Online: 16 January 2024
Declarations
:
: The study was approved by the Local Ethical Committee (H-6-2014-006) and the Danish Data Protection Agency, Capital Region of Copenhagen. The study complied with the latest Declaration of Helsinki.
: Authors UK, AHS, MW, JF, and SGH declare no conflicts of interest. HZ has served on scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, and Biogen. KB has served as a consultant or on advisory boards for Alzheon, BioArtic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Pfizer, and Roche Diagnostics. HZ and KB are co-founders of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg. KWM reports having received consultancy fees from Lundbeck and Janssen in the past 3 years. LVK has within the preceding 3 years been a consultant for Lundbeck and Teva.